<DOC>
	<DOCNO>NCT02421471</DOCNO>
	<brief_summary>This study mandatory post launch observational study South Korea 3.000 patient receive treatment first time new medicinal product , ingenol mebutate gel ( Picato速 ) , approve topical treatment actinic keratosis . Each patient observe 8 week treatment completion .</brief_summary>
	<brief_title>PMS Evaluate Safety Efficacy Picato速 Gel</brief_title>
	<detailed_description>Picato速 ( ingenol mebutate ) gel new topical therapy Actinic Keratosis ( AK ) adult approve Korean Ministry Food Drug Safety ( MFDS ) December 2013 . For AK face scalp 0.015 percent gel approve applied day 3 consecutive day , AK trunk extremity 0.05 percent gel approve applied day 2 consecutive day . The re-examination period Picato速 run December 2013 December 2019 , least 3,000 patient prescribed ingenol mebutate gel first time investigator 's medical judgment must document standard Post Marketing Surveillance ( PMS ) study . Each patient observe 8 week follow application ingenol mebutate gel . If patient unable visit PMS site , investigator may contact patient phone ass safety .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Adult patient AK First time treatment ingenol mebutate 0.015 0.05 percent gel Children adolescent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>topical treatment</keyword>
	<keyword>ingenol mebutate</keyword>
</DOC>